Protocol Ledger

NCT06904261 · Phase III · RECRUITING

A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants

Interventional Phase III clinical trial protocol NCT06904261 sponsored by Amicus Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-01-08 Enrollment: 8 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06904261
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)8 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06904261
Protocol FieldVerified Registry Value
NCT IdentifierNCT06904261
Consolidated Lead SponsorAmicus Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment8 participants (ESTIMATED)
Registered Start Date2026-01-08
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06904261
Hospital Research SiteLocationSite Profile
Emory Winship Cancer InstituteAtlanta, GAOpen Hospital Dossier ->
Cincinnati Children's Hospital Medical CenterCincinnati, OHOpen Hospital Dossier ->
UPMC Children's Hospital of PittsburghPittsburgh, PAOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI